KNKimberly P. Newton

Kimberly P. Newton

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Kimberly P. Newton has a total of 107 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Alcohol use trajectories and liver enzyme changes in adolescents with MASLD: A longitudinal multicenter cohort

    by Nhat Quang N. Thai, Laura A. Wilson, Cynthia A. Behling, Jeanne M. Clark, Jean P. Molleston, Kimberly P. Newton, Rany M. Salem, Gretchen Bandoli, John Alcaraz, Noe Crespo, et al.

    Objectives: To characterize longitudinal patterns of alcohol use and evaluate associations with liver enzyme changes in youth with metabolic dysfunction–associated steatotic liver disease (MASLD). Methods: We analyzed 1172 children with biopsy-confirmed MASLD and longitudinal Alcohol Use Disorders Identification Test–Consumption (AUDIT-C) data. Group-based trajectory modeling identified alcohol use patterns over time. Linear mixed models assessed associations between alcohol trajectory groups and alanine aminotransferase (ALT), aspartate aminotransferase (AST), and gamma-glutamyl transferase (GGT). Generalized linear mixed models evaluated predictors of alcohol use, including age, sex, body mass index (BMI), fibrosis stage, and household income. Results: Among participants diagnosed with MASLD in childhood, 206 (17.6%) reported alcohol use during adolescence or early adulthood. Three alcohol-use groups were identified: non-users, adolescent initiators, and adult initiators. Heavy episodic drinking was reported by 48 of 71 adolescent initiators (67.6%) and 53 of 135 adult initiators (39.3%). Compared with non-users, alcohol initiators had lower liver chemistry values at enrollment but greater annual increases during follow-up. Adolescent initiators had a 4% greater annual increase in ALT, while adult initiators had 6%, 4%, and 3% greater annual increases in ALT, AST, and GGT, respectively. Conclusions: Nearly 1 in 5 youth with MASLD reported alcohol use during adolescence or early adulthood despite ongoing subspecialty care. Alcohol-use trajectories were associated with greater annual increases in liver chemistries, particularly among participants with heavy episodic drinking. These findings support routine alcohol screening and developmentally tailored anticipatory guidance in pediatric MASLD care.

  • Reply: The PNPLA3 paradox—Does genotype modify the clinical utility of the MASLD framework in children?

    by Tin Bo Nicholas Lam, Nidhi P. Goyal, Kimberly P. Newton, Jeffrey B. Schwimmer


  • Open Access

    Neighborhood disparities and metabolic dysfunction–associated steatotic liver disease in children with overweight or obesity

    by Ananya Venkatesh, Nhat Thai, Patricia Ugalde-Nicalo, Martha R. Smith, Laura E. Bauman, Cynthia A. Behling, Kimberly P. Newton, Romeo C. Ignacio, Jeffrey B. Schwimmer

    Background: Metabolic dysfunction–associated steatotic liver disease (MASLD) is the most common pediatric liver disease, yet known biological risk factors do not fully explain its development. This study evaluated the association between social determinants of health (SDH)—including income, education, housing, and environmental factors—and MASLD in children with overweight or obesity. Methods: This cross-sectional study included children with overweight or obesity evaluated in pediatric gastroenterology clinics, stratified by the presence of MASLD. Participants’ residential census tracts were linked to the California Healthy Places Index (HPI), where higher scores indicate greater socioeconomic advantage. Generalized linear regression models, adjusted for age, sex, race, ethnicity, and body mass index (BMI), assessed associations between SDH and MASLD. Results: The study included 888 children (mean age: 12.8±2.9 y, mean BMI: 30.6±6.4 kg/m 2 ). Children with MASLD lived in neighborhoods with significantly lower HPI scores than those without MASLD (−0.22 vs. −0.03; 41st vs. 49th percentile, p =0.01). They also resided in areas with significantly lower socioeconomic advantage across multiple HPI subdomains, including housing (−0.16 vs. 0.03; 44th vs. 51st percentile, p p <0.001) scores. Conclusions: Children with MASLD were more likely to live in neighborhoods with greater socioeconomic and environmental disadvantage than their peers with overweight or obesity but without MASLD. These findings highlight potential SDH targets for public health interventions aimed at reducing MASLD risk in children.


  • Open Access

    Reclassifying pediatric NAFLD using the steatotic liver disease framework: A multicenter retrospective study from the NASH CRN

    by Tin Bo Nicholas Lam, Katherine P. Yates, Sheila L. Noon, Kimberly P. Newton, Mark H. Fishbein, Jean P. Molleston, Stavra A. Xanthakos, Ajay K. Jain, Miriam B. Vos, Niviann M. Blondet, et al.

    Background and Aims: The terminology for hepatic steatosis and NAFLD was revised under the umbrella of steatotic liver disease, with metabolic dysfunction–associated steatotic liver disease (MASLD) as the primary subtype. MASLD is defined by hepatic steatosis plus at least 1 cardiometabolic risk factor. A new category, Met-ALD, describes MASLD with alcohol consumption below the defined thresholds for alcohol-associated liver disease (ALD). While adult studies have demonstrated strong concordance between NAFLD and MASLD, the applicability of this framework in children remains unclear. Approach and Results: We assessed children clinically diagnosed with NAFLD and enrolled in the NASH CRN who had available liver histology. Clinical and demographic data, including body mass index, hepatotoxic medication use, and alcohol intake, were analyzed. Liver biopsies were centrally reviewed to confirm hepatic steatosis and evaluate for alternative etiologies. Participants were reclassified using the steatotic liver disease framework. Among 1019 children diagnosed with NAFLD, 858 (84%) met MASLD criteria. The average number of cardiometabolic risk factors per participant was 2.7±1.1; 41 (4.7%) met all five. Thirty-three participants (3.2%) were reclassified as Met-ALD, a prevalence that rose to 5.4% among adolescents. Sixty-six children (6.5%) were reclassified as drug-induced steatotic liver disease. Conclusions: Most children with NAFLD met MASLD criteria, but nearly 1 in 6 were reclassified based on alcohol use or medication exposure. These findings highlight the need for a systematic diagnostic approach accounting for metabolic risk factors, alcohol use, and medication-related liver injury.


  • Top Cited Papers

    Long-term mortality and extrahepatic outcomes in 1096 children with MASLD: A retrospective cohort study

    by Jeffrey B. Schwimmer, Nhat Quang N. Thai, Sheila L. Noon, Patricia Ugalde-Nicalo, Sabina R. Anderson, Lauren F. Chun, Rhys S. David, Nidhi P. Goyal, Kimberly P. Newton, Eleanor G. Hansen, et al.

    Background & Aims: Metabolic dysfunction-associated steatotic liver disease (MASLD) is the most common chronic liver disease in children, but its long-term outcomes are poorly understood. This study aimed to quantify mortality rates, identify causes of death, and evaluate the incidence of cirrhosis and extrahepatic outcomes in children with pediatric-onset MASLD. Approach & Results: The Longitudinal InVestigation Evaluating Results of Steatosis (LIVERS) study is a single-center, retrospective cohort study conducted at Rady Children’s Hospital San Diego. We included 1,096 children aged 2–18 years who were diagnosed with MASLD between 2000 and 2017 and followed for a mean of 8.5 years. Mortality was ascertained via the National Death Index, and comorbidities were assessed through follow-up research visits and medical records. Overall, 3.4% of children died, yielding a mortality rate of 398 per 100,000 person-years; nearly half of these deaths were liver-related. Male sex and lower high-density lipoprotein levels independently predicted increased mortality risk. The cumulative incidence of cirrhosis was 4.7%. High incidence rates of extrahepatic comorbidities were observed, including dyslipidemia (3,664 per 100,000 person-years), hypertension (1,901), obstructive sleep apnea (1,185), and type 2 diabetes (911). Conclusions: Pediatric MASLD is associated with significant premature mortality and a substantial burden of hepatic and extrahepatic comorbidities. These findings highlight the need for timely screening, early intervention, and long-term management strategies to improve outcomes for children with MASLD. Export


  • Longitudinal response to standard of care in pediatric metabolic dysfunction–associated steatotic liver disease: Rates of improvement and worsening, and factors associated with outcomes

    by Kimberly P. Newton, Dulshan Jayasekera, Amanda L. Blackford, Cynthia Behling, Laura A. Wilson, Mark H. Fishbein, Jean P. Molleston, Stavra A. Xanthakos, Miriam B. Vos, Jeffrey B. Schwimmer, et al.

    Background and Aims: Longitudinal outcomes in children with metabolic dysfunction–associated steatotic liver disease (MASLD) remain unclear due to the absence of a standardized monitoring approach. This study aimed to (1) define improvement and worsening in children with MASLD, (2) estimate rates of improvement or deterioration with the standard of care (SOC) over 1 and 2 years, and (3) identify baseline and longitudinal factors associated with improvement or worsening. Approach and Results: Using data from 2 large randomized controlled trials, we derived definitions for composite improvement and worsening of MASLD based on associations between changes in ALT, GGT, and liver histology after 1 and 2 years. Improvement was defined as ≥40% decrease in ALT and ≥20% decrease in GGT and worsening as ≥20% increase in both ALT and GGT. We applied definitions to a cohort of 440 children with MASLD. After 1 year of SOC, 22% of children with MASLD showed improvement, increasing to 31% after 2 years. However, 20% showed worsening after both 1 and 2 years despite receiving SOC. Logistic regression analysis, employing stepwise model selection, identified changes in body mass index z-score and cholesterol to be most associated with improvement or deterioration. Conclusions: This study developed criteria for improvement and worsening in children with MASLD over 1 and 2 years of follow-up. With SOC, over one-quarter of children are likely to improve while one-fifth of children are likely to worsen. Targeting interventions that affect body mass index and lipid parameters may help improve MASLD over time.


  • Dietary sugar restriction reduces hepatic de novo lipogenesis in adolescent boys with fatty liver disease

    by Catherine C. Cohen, Kelvin W. Li, Adina L. Alazraki, Carine Beysen, Carissa A. Carrier, Rebecca L. Cleeton, Mohamad Dandan, Janet Figueroa, Jack Knight-Scott, Cynthia J. Knott, et al.

    BACKGROUND. Hepatic de novo lipogenesis (DNL) is elevated in nonalcoholic fatty liver disease (NAFLD). Improvements in hepatic fat by dietary sugar reduction may be mediated by reduced DNL, but data are limited, especially in children. We examined the effects of 8 weeks of dietary sugar restriction on hepatic DNL in adolescents with NAFLD and correlations between DNL and other metabolic outcomes. METHODS. Adolescent boys with NAFLD (n = 29) participated in an 8-week, randomized controlled trial comparing a diet low in free sugars versus their usual diet. Hepatic DNL was measured as percentage contribution to plasma triglyceride palmitate using a 7-day metabolic labeling protocol with heavy water. Hepatic fat was measured by magnetic resonance imaging–proton density fat fraction. RESULTS. Hepatic DNL was significantly decreased in the treatment group (from 34.6% to 24.1%) versus the control group (33.9% to 34.6%) (adjusted week 8 mean difference: –10.6% [95% CI: –19.1%, –2.0%]), which was paralleled by greater decreases in hepatic fat (25.5% to 17.9% vs. 19.5% to 18.8%) and fasting insulin (44.3 to 34.7 vs. 35.5 to 37.0 μIU/mL). Percentage change in DNL during the intervention correlated significantly with changes in free-sugar intake (r = 0.48, P = 0.011), insulin (r = 0.40, P = 0.047), and alanine aminotransferase (ALT) (r = 0.39, P = 0.049), but not hepatic fat (r = 0.13, P = 0.532). CONCLUSION. Our results suggest that dietary sugar restriction reduces hepatic DNL and fasting insulin, in addition to reductions in hepatic fat and ALT, among adolescents with NAFLD. These results are consistent with the hypothesis that hepatic DNL is a critical metabolic abnormality linking dietary sugar and NAFLD. TRIAL REGISTRY. ClinicalTrials.gov NCT02513121. FUNDING. The Nutrition Science Initiative (made possible by gifts from the Laura and John Arnold Foundation, Ambrose Monell Foundation, and individual donors), the UCSD Altman Clinical and Translational Research Institute, the NIH, Children’s Healthcare of Atlanta and Emory University’s Children’s Clinical and Translational Discovery Core, Children’s Healthcare of Atlanta and Emory University Pediatric Biostatistical Core, the Georgia Clinical and Translational Science Alliance, and the NIH National Institute of Diabetes, Digestive, and Kidney Disease.


  • Magnetic resonance elastography measured shear stiffness as a biomarker of fibrosis in pediatric nonalcoholic fatty liver disease

    by Jeffrey B. Schwimmer, Cynthia Behling, Jorge Eduardo Angeles, Melissa Paiz, Janis Durelle, Jonathan Africa, Kimberly P. Newton, Elizabeth M. Brunt, Joel E. Lavine, Stephanie H. Abrams, et al.

    Magnetic resonance elastography (MRE) is a promising technique for noninvasive assessment of fibrosis, a major determinant of outcome in nonalcoholic fatty liver disease (NAFLD). However, data in children are limited. The purpose of this study was to determine the accuracy of MRE for the detection of fibrosis and advanced fibrosis in children with NAFLD and to assess agreement between manual and novel automated reading methods. We performed a prospective, multicenter study of two‐dimensional (2D) MRE in children with NAFLD. MR elastograms were analyzed manually at two reading centers, and using a new automated technique. Analysis using each approach was done independently. Correlations were determined between MRE analysis methods and fibrosis stage. Thresholds for classifying the presence of fibrosis and of advanced fibrosis were computed and cross‐validated. In 90 children with a mean age of 13.1 ± 2.4 years, median hepatic stiffness was 2.35 kPa. Stiffness values derived by each reading center were strongly correlated with each other (r = 0.83). All three analyses were significantly correlated with fibrosis stage (center 1, ρ = 0.53; center 2, ρ = 0.55; and automated analysis, ρ = 0.52; P < 0.001). Overall cross‐validated accuracy for detecting any fibrosis was 72.2% for all methods (95% confidence interval [CI], 61.8%‐81.1%). Overall cross‐validated accuracy for assessing advanced fibrosis was 88.9% (95% CI, 80.5%‐94.5%) for center 1, 90.0% (95% CI, 81.9%‐95.3%) for center 2, and 86.7% (95% CI, 77.9%‐92.9%) for automated analysis. Conclusion: 2D MRE can estimate hepatic stiffness in children with NAFLD. Further refinement and validation of automated analysis techniques will be an important step in standardizing MRE. How to best integrate MRE into clinical protocols for the assessment of NAFLD in children will require prospective evaluation. (Hepatology 2017;66:1474–1485)


  • Lifestyle Interventions Including Nutrition, Exercise, and Supplements for Nonalcoholic Fatty Liver Disease in Children

    by Jonathan A. Africa, Kimberly P. Newton, Jeffrey B. Schwimmer

    Nonalcoholic fatty liver disease (NAFLD) is the most common cause of liver disease among children. Lifestyle interventions, such as diet and exercise, are frequently recommended. Children with NAFLD have a distinct physiology that is different from obesity alone and has the potential to influence lifestyle treatments. Studies of diet alone in the treatment of pediatric NAFLD have focused on sugar and carbohydrate, but did not indicate any one dietary approach that was superior to another. For children who are obese and have NAFLD, weight loss may have a beneficial effect regardless of the diet used. Exercise is widely believed to improve NAFLD because a sedentary lifestyle, poor aerobic fitness, and low muscle mass are all risk factors for NAFLD. However, there have been no randomized controlled trials of exercise as a treatment for children with NAFLD. Studies of the combination of diet and exercise suggest a potential for improvement in serum alanine aminotransferase activity and/or magnetic resonance imaging liver fat fraction with intervention. There is also enthusiasm for the use of dietary supplements; however, studies in children have shown inconsistent effects of vitamin E, fish oil, and probiotics. This review presents the available data from studies of lifestyle intervention and dietary supplements published to date and highlights challenges that must be addressed in order to advance the evidence base for the treatment of pediatric NAFLD.